Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

References

• Anonymous. (2000). Exemestane for advanced breast cancer. Med Lett Drugs Ther 42:35–36.
   PubMed Web of Science ®Google Scholar
• Antoniou, T., Tseng, A. L. (2005). Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44:111–145.
   PubMed Web of Science ®Google Scholar
• Apak, T. I., Duffel, M. W. (2004). Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug Metab Dispos 32:1501–1508.
   PubMed Web of Science ®Google Scholar
• AstraZeneca (2006). Arimidex anastrozole tablets. Available at: www1.astrazeneca-us.com/pi/arimidex.pdf.2006. Wilming, DE. USA. Access weblink: Jan 2007.
   Google Scholar
• Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., van Leeuwen, F. E. (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356:881–887.
   PubMed Web of Science ®Google Scholar
• Berkovitz, G. D., Brown, T. R., Fujimoto, M. (1987). Aromatase activity in human skin fibroblasts grown in cell culture. Steroids 50(1–3):281–295.
   PubMedGoogle Scholar
• Bernstein, L., Deapen, D., Cerhan, J. R., Schwartz, S. M., Liff, J., McGann-Maloney, E., et al. (1999). Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654–1662.
   PubMed Web of Science ®Google Scholar
• Blevins-Primeau, A. S., Sun, D., Chen, G., Sharma, A. K., Gallagher, C. J., Amin, S., et al. (2009). Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res Epub Feb 24.
   PubMed Web of Science ®Google Scholar
• Boccardo, F., Rubagotti, A., Puntoni, M., Guglielmini, P., Amoroso, D., Fini, A., et al. (2005). Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138–5147.
   PubMed Web of Science ®Google Scholar
• Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W., White, I. N. (2002). Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23:1897–1901.
   PubMed Web of Science ®Google Scholar
• Borges, S., Desta, Z., Li, L., Skaar, T. C., Ward, B. A., Nguyen, A., et al. (2006). Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61–74.
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff, U., Mey, U., Green, M. D., Tephly, T. R. (2000). Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 28:869–872.
   PubMed Web of Science ®Google Scholar
• Bulun, S. E., Simpson, E. R. (1994). Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab 78:428–432.
   PubMed Web of Science ®Google Scholar
• Buzdar, A. U., Guastalla, J. P., Nabholtz, J. M., Cuzick, J., Group, A. T. (2006). Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) Trial. Cancer 107:472–480.
   PubMed Web of Science ®Google Scholar
• Buzzetti, F., Di Salle, E., Longo, A., Briatico, G. (1993). Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione). Steroids 58:527–532.
   PubMed Web of Science ®Google Scholar
• Chen, G., Yin, S., Maiti, S., Shao, X. (2002). 4-hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol 16:279–285.
   PubMed Web of Science ®Google Scholar
• Coates, A. S., Keshaviah, A., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., et al. (2007). Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492.
   PubMed Web of Science ®Google Scholar
• Coffman, B. L., King, C. D., Rios, G. R., Tephly, T. R. (1998). The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73–77.
   PubMed Web of Science ®Google Scholar
• Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., et al. (2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised, controlled study. Lancet Oncol 8:119–127.
   PubMed Web of Science ®Google Scholar
• Coller, J. K. (2003). Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. Clin Exp Pharmacol Physiol 30:845–848.
   PubMed Web of Science ®Google Scholar
• Coller, J. K., Krebsfaenger, N., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., et al. (2002). The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157–167.
   PubMed Web of Science ®Google Scholar
• Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E., et al. (2007). Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised, controlled trial. Lancet 369:559–570.
   PubMed Web of Science ®Google Scholar
• Crewe, H. K., Ellis, S. W., Lennard, M. S., Tucker, G. T. (1997). Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171–178.
   PubMed Web of Science ®Google Scholar
• Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., Gillam, E. M. (2002). Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy, and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869–874.
   PubMed Web of Science ®Google Scholar
• Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., et al. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300.
   PubMed Web of Science ®Google Scholar
• Dehal, S. S., Kupfer, D. (1997). CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402–3406.
   PubMed Web of Science ®Google Scholar
• Desta, Z., Ward, B. A., Soukhova, N. V., Flockhart, D. A. (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075.
   PubMed Web of Science ®Google Scholar
• Dowsett, M., Cuzick, J., Howell, A., Jackson, I. (2001). Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the Arimidex and Tamoxifen, Alone or in Combination (ATAC) Trial. Br J Cancer 85:317–324.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. The Early Breast Cancer Trialists’ Collaborative Group. (1998). Lancet 351:1451–1467.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Eisen, A., Trudeau, M., Shelley, W., Messersmith, H., Pritchard, K. I. (2008). Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 34:157–174.
   PubMed Web of Science ®Google Scholar
• Elahi, A., Bendaly, J., Zheng, Z., Muscat, J. E., Richie, J. P., Jr., Schantz, S. P., et al. (2003). Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 98:872–880.
   PubMed Web of Science ®Google Scholar
• Falany, C. N. (1997). Enzymology of human cytosolic sulfotransferases. FASEB J 11:206–216.
   PubMed Web of Science ®Google Scholar
• FDA. (2004). Femara. Silver Spring, Maryland, USA: U.S. Food and Drug Administration. Available at: //www.fda.gov/cder/foi/label/2004/020726s011lbl.pdf. Access date for weblink: Feb 2007.
   Google Scholar
• Ferretti, G., Bria, E., Giannarelli, D., Felici, A., Papaldo, P., Fabi, A., et al. (2006). Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 94:1789–1796.
   PubMed Web of Science ®Google Scholar
• Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M. (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537.
   PubMed Web of Science ®Google Scholar
• Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388.
   PubMed Web of Science ®Google Scholar
• Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S., Baum, M. (2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC Trial. Lancet Oncol 9:45–53.
   PubMed Web of Science ®Google Scholar
• Furr, B. J., Jordan, V. C. (1984). The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127–205.
   PubMed Web of Science ®Google Scholar
• Gallagher, C. J., Muscat, J. E., Hicks, A. N., Zheng, Y., Dyer, A. M., Chase, G. A., et al. (2007). The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 16:823–828.
   PubMed Web of Science ®Google Scholar
• Goetz, M. P., Kamal, A., Ames, M. M. (2008). Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83:160–166.
   PubMed Web of Science ®Google Scholar
• Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., et al. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113–121.
   PubMed Web of Science ®Google Scholar
• Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., et al. (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318.
   PubMed Web of Science ®Google Scholar
• Green, M. D., Tephly, T. R. (1996). Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 24:356–363.
   PubMed Web of Science ®Google Scholar
• Green, M. D., Tephly, T. R. (1998). Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26:860–867.
   PubMed Web of Science ®Google Scholar
• Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J. F., et al. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62.
   Google Scholar
• Howell, A., Group, A. T. (2006). Analysis of fracture risk factors from the Arimadex, Tamoxifen, Alone or in Combination (ATAC) Trial: 5-year data [abstract]. J Clin Oncol 24:A563.
   PubMedGoogle Scholar
• Howell, A., Howell, S. J., Evans, D. G. (2003). New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemother Pharmacol 52(Suppl 1):S39–S44.
   PubMedGoogle Scholar
• Hozumi, Y., Suemasu, K., Takehara, M., Takei, H., Aihara, T., Tamura, M. (2006). The effect of exemestane, anastrozole, and tamoxifen on the lipidemic profile of postmeonpausal early breast cancer patients: preliminary results of NSAS (National Surgical Adjusvant Study). Breast Cancer Res Treat 100:A4051.
   Google Scholar
• Hu, Y., Dehal, S. S., Hynd, G., Jones, G. B., Kupfer, D. (2003). CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat, and human liver microsomes. Xenobiotica 33:141–151.
   PubMed Web of Science ®Google Scholar
• Huang, Y. H., Galijatovic, A., Nguyen, N., Geske, D., Beaton, D., Green, J., et al. (2002). Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 12:287–297.
   PubMedGoogle Scholar
• Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., Berthou, F. (1991). Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911–1919.
   PubMed Web of Science ®Google Scholar
• Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K. H., et al. (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39.
   PubMed Web of Science ®Google Scholar
• Johnson, M. D., Zuo, H., Lee, K. H., Trebley, J. P., Rae, J. M., Weatherman, R. V., et al. (2004). Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151–159.
   PubMed Web of Science ®Google Scholar
• Jordan, V. C., Collins, M. M., Rowsby, L., Prestwich, G. (1977). A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305–316.
   PubMed Web of Science ®Google Scholar
• Kaku, T., Ogura, K., Nishiyama, T., Ohnuma, T., Muro, K., Hiratsuka, A. (2004). Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 67:2093–2102.
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen, B. S., Norman, M. J., Eckert, R. L., Peltz, S. W., Mangel, W. F. (1984). Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112–119.
   PubMed Web of Science ®Google Scholar
• Kim, S. Y., Suzuki, N., Santosh Laxmi, Y. R., Rieger, R., Shibutani, S. (2003). Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol 16:1138–1144.
   PubMed Web of Science ®Google Scholar
• Lazarus, P., Blevins-Primeau, A. S., Zheng, Y., Sun, D. (2009). Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci 1155:99–111.
   PubMed Web of Science ®Google Scholar
• Lien, E. A., Solheim, E., Kvinnsland, S., Ueland, P. M. (1988). Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48:2304–2308.
   PubMed Web of Science ®Google Scholar
• Lien, E. A., Solheim, E., Lea, O. A., Lundgren, S., Kvinnsland, S., Ueland, P. M. (1989). Distribution of 4-hydroxy-N- desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49:2175–2183.
   PubMed Web of Science ®Google Scholar
• Lim, L., Desta, Z., Rae, J., Flockhart, D., Skaar, T. (2004). Gene expression profiles of 4-hydroxy-N-desmethyltamoxifen (endoxifen) and 4-hydroxytamoxifen (4OHTAM) treated human breast cancer cells determined by cDNA microarray analysis. Clin Pharmacol Ther 75:49.
   PubMedGoogle Scholar
• Lim, Y. C., Desta, Z., Flockhart, D. A., Skaar, T. C. (2005). Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has antiestrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478.
   PubMed Web of Science ®Google Scholar
• Lonning, P. E., Lien, E. A., Lundgren, S., Kvinnsland, S. (1992). Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22:327–358.
   PubMed Web of Science ®Google Scholar
• Mareck, U., Geyer, H., Guddat, S., Haenelt, N., Koch, A., Kohler, M., et al. (2006). Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20:1954–1962.
   PubMed Web of Science ®Google Scholar
• Markopoulos, C., Polychronis, A., Zobolas, V., Xepapadakis, G., Papadiamantis, J., Koukouras, D., et al. (2005). The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek substudy. Breast Cancer Res Treat 93:61–66.
   PubMed Web of Science ®Google Scholar
• Matsumine, H., Hirato, K., Yanaihara, T., Tamada, T., Yoshida, M. (1986). Aromatization by skeletal muscle. J Clin Endocrinol Metab 63:717–720.
   PubMed Web of Science ®Google Scholar
• McCarroll, S. A., Hadnott, T. N., Perry, G. H., Sabeti, P. C., Zody, M. C., Barrett, J. C., et al. (2006). Common deletion polymorphisms in the human genome. Nat Genet 38:86–92.
   PubMed Web of Science ®Google Scholar
• McDonald, C. C., Stewart, H. J. (1991). Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303:435–437.
   PubMed Web of Science ®Google Scholar
• Means, G. D., Kilgore, M. W., Mahendroo, M. S., Mendelson, C. R., Simpson, E. R. (1991). Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol Endocrinol 5:2005–2013.
   PubMed Web of Science ®Google Scholar
• Meier, C. R., Jick, H. (1998). Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608–612.
   PubMed Web of Science ®Google Scholar
• Murata, M., Warren, E. H., Riddell, S. R. (2003). A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 197:1279–1289.
   PubMed Web of Science ®Google Scholar
• Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., Yokoi, T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461–1464.
   PubMed Web of Science ®Google Scholar
• Nelson, L. R., Bulun, S. E. (2001). Estrogen production and action. J Am Acad Dermatol 45(3 Suppl):S116–S124.
   PubMed Web of Science ®Google Scholar
• Nishiyama, T., Ogura, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., et al. (2002). Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817–1830.
   PubMed Web of Science ®Google Scholar
• Osborne, C. K. (1998). Tamoxifen in the treatment of breast cancer. NEJM 339:1609–1618.
   PubMed Web of Science ®Google Scholar
• Pfizer. (2007). Aromasin exemestane tablets. Available at: www.pfizer.com/files/products/uspi_aromasin.pdf. NY, NY, USA. Access date: Oct, 2007.
   Google Scholar
• Perez, E. A., Josse, R. G., Pritchard, K. I., Ingle, J. N., Martino, S., Findlay, B. P., et al. (2006). Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629–3635.
   PubMed Web of Science ®Google Scholar
• Poon, G. K., Chui, Y. C., McCague, R., Llnning, P. E., Feng, R., Rowlands, M. G., et al. (1993). Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 21:1119–1124.
   PubMed Web of Science ®Google Scholar
• Ren, Q., Murphy, S. E., Zheng, Z., Lazarus, P. (2000). O-glucuronidation of the lung carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28:1352–1360.
   PubMed Web of Science ®Google Scholar
• Roselli, C. E., Horton, L. E., Resko, J. A. (1985). Distribution and regulation of aromatase activity in the rat hypothalamus and limbic system. Endocrinology 117:2471–2477.
   PubMed Web of Science ®Google Scholar
• Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., Wilking, N. (1995). Adjuvant tamoxifen therapy for early-stage breast cancer and second primary malignancies. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645–651.
   PubMed Web of Science ®Google Scholar
• Rutqvist, L. E., Mattsson, A. (1993). Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398–1406.
   PubMed Web of Science ®Google Scholar
• Shozu, M., Simpson, E. R. (1998). Aromatase expression of human osteoblast-like cells. Mol Cell Endocrinol 139(1–2):117–129.
   PubMed Web of Science ®Google Scholar
• Sioufi, A., Gauducheau, N., Pineau, V., Marfil, F., Jaouen, A., Cardot, J. M., et al. (1997). Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 18:779–789.
   PubMed Web of Science ®Google Scholar
• Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava, P., et al. (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764.
   PubMed Web of Science ®Google Scholar
• Strassburg, C. P., Strassburg, A., Nguyen, N., Li, Q., Manns, M. P., Tukey, R. H. (1999). Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 338(Pt 2):489–498.
   PubMedGoogle Scholar
• Sun, D., Chen, G., Dellinger, R. W., Duncan, K., Fang, J. L., Lazarus, P. (2006). Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8:R50.
   PubMed Web of Science ®Google Scholar
• Sun, D., Sharma, A. K., Dellinger, R. W., Blevins-Primeau, A. S., Balliet, R. M., Chen, G., et al. (2007). Glucuronidation of active tamoxifen metabolites by the human UDP-glucuronosyltransferases. Drug Metab Dispos 35:2006–2014.
   PubMed Web of Science ®Google Scholar
• Thurlimann, B., Keshaviah, A., Coates, A. S., Mouridsen, H., Mauriac, L., Forbes, J. F., et al. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEJM 353:2747–2757.
   PubMed Web of Science ®Google Scholar
• Tsai-Morris, C. H., Aquilano, D. R., Dufau, M. L. (1985). Cellular localization of rat testicular aromatase activity during development. Endocrinology 116:38–46.
   PubMed Web of Science ®Google Scholar
• Turgeon, D., Carrier, J. S., Levesque, E., Hum, D. W., Belanger, A. (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778–787.
   PubMed Web of Science ®Google Scholar
• van Leeuwen, F. E., Benraadt, J., Coebergh, J. W., Kiemeney, L. A., Gimbrere, C. H., Otter, R., et al. (1994). Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448–452.
   PubMed Web of Science ®Google Scholar
• Wiener, D., Doerge, D. R., Fang, J. L., Upadhyaya, P., Lazarus, P. (2004a). Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32:72–79.
   PubMed Web of Science ®Google Scholar
• Wiener, D., Fang, J. L., Dossett, N., Lazarus, P. (2004b). Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190–1196.
   PubMed Web of Science ®Google Scholar
• Wilson, W., 3rd, Pardo-Manuel de Villena, F., Lyn-Cook, B. D., Chatterjee, P. K., Bell, T. A., Detwiler, D. A., et al. (2004). Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84:707–714.
   PubMed Web of Science ®Google Scholar
• Zheng, Y., Sun, D., Sharma, A. K., Chen, G., Amin, S., Lazarus, P. (2007). Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35:1942–1948.
   PubMed Web of Science ®Google Scholar
• Zheng, Z., Fang, J. L., Lazarus, P. (2002). Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30:397–403.
   PubMed Web of Science ®Google Scholar